Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enavogliflozin in Heart Failure With Preserved Ejection Fraction
NCT06350487Phase 4Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of enavogliflozin in heart failure with preserved ejection fraction (HFpEF), sponsored by Samsung Medical Center. Planned start May 2024; status: not yet recruiting.
02
Drugs
enavogliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06350487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06350487.